Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.

Fischer, Stefanie; Tandstad, Torgrim; Cohn-Cedermark, Gabriella; Thibault, Constance; Vincenzi, Bruno; Klingbiel, Dirk; Albany, Costantine; Necchi, Andrea; Terbuch, Angelika; Lorch, Anja; Aparicio, Jorge; Heidenreich, Axel; Hentrich, Marcus; Wheater, Matthew; Langberg, Carl W; Ståhl, Olof; Fankhauser, Christian Daniel; Hamid, Anis A; Koutsoukos, Konstantinos; Shamash, Jonathan; ... (2020). Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. Journal of clinical oncology, 38(12), pp. 1322-1331. American Society of Clinical Oncology 10.1200/JCO.19.01876

[img] Text
JCO relapse after adjuvant BEP.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (811kB) | Request a copy

PURPOSE Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One treatment strategy after orchiectomy is adjuvant chemotherapy. Little is known about the outcome of patients who experience relapse after such treatment. PATIENTS AND METHODS Data from 51 patients with CSI NS who experienced a relapse after adjuvant bleomycin, etoposide, and cisplatin (BEP) from 18 centers/11 countries were collected and retrospectively analyzed. Primary outcomes were overall and progression-free survivals calculated from day 1 of treatment at first relapse. Secondary outcomes were time to, stage at, and treatment of relapse and rate of subsequent relapses. RESULTS Median time to relapse was 13 months, with the earliest relapse 2 months after start of adjuvant treatment and the latest after 25 years. With a median follow-up of 96 months, the 5-year PFS was 67% (95% CI, 54% to 82%) and the 5-year OS was 81% (95% CI, 70% to 94%). Overall, 19 (37%) of 51 relapses occurred later than 2 years. Late relapses were associated with a significantly higher risk of death from NS (hazard ratio, 1.10 per year; P = .01). Treatment upon relapse was diverse: the majority of patients received a combination of chemotherapy and surgery. Twenty-nine percent of patients experienced a subsequent relapse. At last follow-up, 41 patients (80%) were alive and disease-free, eight (16%) had died of progressive disease, and one patient (2%) each had died from therapy-related or other causes. CONCLUSION Outcomes of patients with relapse after adjuvant BEP seem better compared with patients who experience relapse after treatment of metastatic disease but worse compared with those who have de-novo metastatic disease. We found a substantial rate of late and subsequent relapses. There seem to be three patterns of relapse with different outcomes: pure teratoma, early viable NS relapse (< 2 years), and late viable NS relapse (> 2 years).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Beyer, Jörg and Gillessen, Silke

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

22 Jan 2020 08:18

Last Modified:

17 Apr 2020 01:32

Publisher DOI:

10.1200/JCO.19.01876

PubMed ID:

31877087

BORIS DOI:

10.7892/boris.139302

URI:

https://boris.unibe.ch/id/eprint/139302

Actions (login required)

Edit item Edit item
Provide Feedback